Tom Bishop Email & Phone Number

Boston, MA, US

Director Of Business Development and the Technology Development Fund, Technology and Innovation Development Office at Boston Children's HospitalResponsible for shaping and delivering high value licenses, research collaboration agreements, and startups across the research enterprise. Develop and implement strategies to optimize the commercial potential of.

Work with early stage biotechnology companies to establish business models and generate profitable revenue in emerging marketsProvide expertise in the areas of strategic planning, investor and public relations, sales & marketing, product development, business development, operations, organizational effectiveness, customer service

Schlieren, Schweiz, CH

Using a unique and patent-protected cell-culture platform, InSphero is the first commercial producer of organotypic, scaffold-free, three-dimensional microtissues for drug development and screening. InSphero provides solutions to pharmaceutical and biotechnological companies in the fields of toxicology, oncology, and metabolic disease.

Early stage startup developing high-precision robotics and patent-pending technology for single-cell analysis in tissues

Baltimore, MD, US

Circulomics is a Johns Hopkins spin-out developing easily accessible mutiplex assays for biomarker and molecular analysis. Circulomics’ innovative Ligo-miR assay platform will be leveraged into a line of microRNA research tools and diagnostic assays, with an initial focus on oncology.

Boston, MA, US

BeRNA Therapeutics was a startup focused on developing and delivering microRNA drugs to treat chronic pain transcutaneously. Due to intellectual property and freedom to operate issues, we dissolved the company.

Acquired by UCB Pharma.Leadership of business development, strategic alliances, and sales & marketing, and matrix leadership of operations. Beryllium enables novel drug discovery by applying structural and functional biology-centric processes and platforms, with the goal of delivering validated starting points for drug development programsTransitioned.

Acquired by AnatraceP&L responsibility for global operations of Microlytic, an innovator and commercial provider of microfluidic devices, vapor diffusion screens, and other consumable lab products for the structural biology market. Leadership of all functions of the North American site, which serves the global market.Developed and implemented Microlytic’s.

P&L leadership for North American operations of Exiqon Inc., the Boston based subsidiary of a Danish biotech. Exiqon provides microRNA focused ISH, qPCR, and microarray research and diagnostic reagents, MultiD GenEx software, NGS, Luminex instruments, and contract laboratory services (miRNA gene expression, biomarker discovery, diagnostic assay.

Participated in fund-raising which resulted in the largest biotech IPO in Danish historyBuilt and led Exiqon's sales & marketing teamDefined, developed and executed the strategy and commercialization plan for Exiqon's miRNA products and services

Business and corporate development. Define and drive strategic account selection criteria, key metrics, KPIs, P&L, alignment within the whole organization

Waltham, MA, US

Responsible for revenue growth strategy, identification of in-licensing opportunities, technical expertise, and focused customer relationship management. Drove creation and expansion of Invitrogen's services business

Ms, Biotechnology, Entrepreneurship Concentration

Mba, Strategy, Marketing, Finance